0O9B.IL - Almirall, S.A.
| Previous close | 8.62 |
| Open | 8.69 |
| Bid | 8.47 x 0 |
| Ask | 8.84 x 0 |
| Day's range | 8.56 - 8.70 |
| 52-week range | 8.11 - 11.29 |
| Volume | |
| Avg. volume | 50,015 |
| Market cap | 1.6B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 54.09 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.18 (2.13%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Business Wire
Almirall’s First Quarter 2023 Results
BARCELONA, Spain, May 08, 2023--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
- Business Wire
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
BARCELONA, Spain, May 01, 2023--Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab’s stable and long-lasting results at
- Business Wire
Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study
BARCELONA, Spain, April 12, 2023--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced the publication in the British Medical Journal (BMJ) of the POSITIVE study protocol, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint. The objective of the study is to capture patients’ overall wellbeing in a real-world setting when in treatment with tildrakizumab, an anti-IL-23p19 biologic indicated for moderate-to-severe p
- Business Wire
Almirall’s Full-Year 2022 Results
BARCELONA, Spain, February 20, 2023--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
- Business Wire
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BARCELONA, Spain, January 04, 2023--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 9-12 January 2023.
- Business Wire
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
BARCELONA, Spain, November 28, 2022--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) project aimed to create a framework for access and reutilization of clinical trial participant data for a fully compliant and ethical ecosystem. FACILITATE main
- Business Wire
Almirall’s Nine-month 2022 Results
BARCELONA, Spain, November 10, 2022--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.
- PR Newswire
Almirall opens a new subsidiary for the Czech Republic and Slovakia
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced the opening of a new affiliate in the Czech Republic and Slovakia to strengthen its presence in these markets and its leadership in Europe in Medical Dermatology. The subsidiary will be managed from Prague by the recently appointed Czech Republic & Slovakia General Manager, David Festa.
- PR Newswire
Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of moderate to severe atopic dermatitis.
- Business Wire
Almirall PROSES study demonstrates appropriate acne treatment decreases the burden of impact on acne sufferers’ social and emotional wellbeing
MALVERN, Pa., October 21, 2022--Almirall, LLC, a global biopharmaceutical company focused on skin health, is excited to announce the release of its privately funded PROSES study at this year’s Fall Clinical Dermatology Conference® in Las Vegas, Nevada, October 20-23, 2022. Over the course of the 12-week study, patients with moderate to severe non-nodular acne vulgaris showed a significant improvement in certain health-related quality of life measures during treatment with sarecycline.
- Business Wire
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
NANJING, China & BARCELONA, Spain, September 29, 2022--Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
- PR Newswire
Almirall: Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE, an interventional phase IV clinical study, which resembled real-life clinical practice. In this study, Ilumetri®▼ (tildrakizumab) is the first IL-23p19 inhibitor to demonstrate improvement on sleep impairment in patients with moderate-to-severe chronic plaque psoriasis. At week 24, the MOS-Sleep (M
- PR Newswire
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, today announced its H1 2022 financial results.
